Mastodon

Ginkor gel (Gel) Instructions for Use

Marketing Authorization Holder

Ipsen Pharma (France)

Manufactured By

Beaufour Ipsen Industrie (France)

ATC Code

C05CA (Bioflavonoids)

Active Substances

Troxerutin (Rec.INN registered by WHO)

Ginkgo biloba (BP British Pharmacopoeia)

Dosage Form

Bottle OTC Icon Ginkor gel Gel for external use 1.4 mg+30 mg/1 g: tube 40 g

Dosage Form, Packaging, and Composition

Gel for external use yellow in color, transparent; the presence of air bubbles is allowed.

100 g
Dry standardized Ginkgo biloba extract 140 mg,
   Including ginkgo flavonol glycosides 24%
   Ginkgolides-bilobalides 6%
Troxerutin 3 g

Excipients : methylparaben 120 mg, propylparaben 30 mg, disodium edetate 20 mg, carbomer (carboxypolymethylene) 1.2 g, isopropanol 8 g, purified water (up to 100 g).

40 g – aluminum tubes (1) – cardboard packs.

Clinical-Pharmacological Group

Venotonic drug for topical application

Pharmacotherapeutic Group

Venotonic agent of plant origin

Pharmacological Action

A drug used for venous circulation disorders. Increases capillary resistance, reduces their increased permeability, optimizes vascular tone, regulates capillary capacity. Promotes increased glucose consumption, elimination of lactates and other metabolic products, and restoration of aerobic glycolysis in tissues.

It has an anti-edema effect, reduces transudation of plasma proteins and leukocyte infiltration by inhibiting phospholipase A2, lipoxygenase and blocking platelet activating factor.

It has antioxidant properties, blocks free radicals and has a protective effect on lysosomal membranes.

Increases the resistance of venous endothelial cells to hypoxia, inhibits the breakdown of collagen microfibers and normalizes the functions of vascular smooth muscle.

Improves the rheological properties of blood by increasing the resistance of erythrocyte membranes and reducing their aggregation. In case of platelet hyperaggregation, the use of the drug reduces the likelihood of thrombus formation.

Indications

  • Functional manifestations of chronic venous insufficiency of the lower extremities with signs of inflammation and trophic skin disorders;
  • Bruises and local hematomas, burning sensation and cramps in the lower extremities;
  • Painful inflammatory reactions to the administration of injectable drugs for the treatment of varicose veins;
  • Superficial phlebitis.

ICD codes

ICD-10 code Indication
I80.0 Phlebitis and thrombophlebitis of superficial vessels of lower extremities
I87.2 Venous insufficiency (chronic) (peripheral)
T14.0 Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect)
ICD-11 code Indication
BD70.0 Superficial thrombophlebitis of lower extremities
BD74.Z Chronic venous insufficiency of lower extremities, unspecified
EH92 Dermatoses provoked by friction or mechanical impact
EH92.1 Blister due to friction
ND56.0 Superficial injury of unspecified body region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Apply the gel to clean, intact skin on the affected area.

Determine the amount used by the size of the skin surface requiring treatment.

Use a quantity approximately equal to the volume of a hazelnut for an area the size of the lower leg’s posterior surface.

Administer the preparation two to four times daily.

Perform a light massage during each application until the gel is fully absorbed.

Continue treatment for the entire duration prescribed by a physician.

Do not apply to mucous membranes, eczematous skin, or open wounds.

Avoid exposing the treated skin areas to direct sunlight after application.

Adverse Reactions

Possible local reactions.

Contraindications

Currently, no contraindications have been established.

Use in Pregnancy and Lactation

Data on the safety and efficacy of the drug during pregnancy and lactation (breastfeeding) have not been provided.

In experimental studies, it was found that the drug does not have a teratogenic effect.

Special Precautions

Ginkor gel should not be applied to mucous membranes, or to areas of skin with eczema or open ulcerations.

Exposure of the treated skin areas to sunlight should be avoided.

Overdose

To date, no cases of Ginkor gel overdose have been reported.

Drug Interactions

No clinically significant interaction of Ginkor gel with other drugs has been established.

Storage Conditions

The drug should be stored at a temperature not exceeding 25°C (77°F).

Pharmacy supply terms

The drug is approved for use as an over-the-counter product.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS